Genomtec S.A.

Regulatory Filings • Jan 28, 2025

Report Content TheManagement Board of Genomtec S.A. with its registered office in Wrocław(_#8216;Issuer', _#8216;Company') announces that today, i.e. January 28, 2025, ithas become aware that a patent application has been filed on behalf ofthe Company with the British Patent Office for a patent protection foran invention in the area of diagnostics of single-nucleotide geneticvariants. The Company's patent strategy assumes extended protection forthe invention in question under the international PCT procedure. Thefiling of the application for patent protection of the developedtechnology is the culmination of complex laboratory work that hasresulted in the creation of a methodology allowing the use of modifiedSNAAT/LAMP technology in the highly precise diagnosis ofsingle-nucleotide genetic alterations, including in the field ofoncology. The developed technique is particularly relevant for mixturescontaining both mutated and wild-type material, as is the case, forexample, with samples in the so-called liquid biopsy technique. At thesame time, the potential applications of the method go beyond oncologyand beyond medicine - the method will also be able to be used wherevergenetic variants need to be diagnosed, both in clinical diagnostics andin veterinary medicine, food safety, among others. The developedmethodology, in combination with the technique described in the 27/2023report, allows for comprehensive diagnosis of clinically relevantgenetic variants that form the basis for proper decisions on the choiceof therapy in oncology and other areas.

Accordingto the Issuer, patent protection in the oncology project may have apositive impact on the Company's ongoing M_amp;A process.